Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, October 7, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Bavarian Nordic's ongoing Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine, which started to include subjects in the United States in September, will also start to include subjects in Denmark in October. The Danish part of the study will be conducted at hospitals on Zealand, Jutland and Funen.
Danish subjects included in the study will assist in the evaluation of the ABNCoV2 vaccine compared to a licensed mRNA-based vaccine, and they will receive one of these vaccines.
If the Phase III clinical trial is successful, Denmark will be one of the first countries to receive doses of the ABNCoV2 vaccine after regulatory approval. This is due to an agreement between the Danish state and Bavarian Nordic that was signed in 2021, where the Danish state agreed to co-finance the final part of the development program in exchange for doses of the vaccine once it is approved.
People who would like to participate in this Phase III trial can contact Bavarian Nordic via telephone on +45 24 67 34 85 or via email on info@bavarian-nordic.com.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se